What is REPL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.26B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for REPL?

P/E (TTM) is n/a and 52-week range is $1.50 to $16.33 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s REPL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for REPL?

The company profile lists net income (TTM) near $-266M, EPS (TTM) near $-3.16 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Replimune Group Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Woburn, Massachusetts, US, 84M shares outstanding, ISIN US76029N1063 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Replimune Group Inc

$REPL

Health Care · Biotechnology

IR Run Scenarios

$13.42

+2.91%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Employees

479

Website

www.replimune.com/

IPO

2018-07-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)